We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+3.54%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.45B
AUM Growth
-$54.5M
Cap. Flow
+$154M
Cap. Flow %
10.62%
Top 10 Hldgs %
43.38%
Holding
129
New
42
Increased
32
Reduced
24
Closed
24

Top Buys

Rank Stock Value
1
LH icon
Labcorp
LH
+$37.6M
2
CYH icon
Community Health Systems
CYH
+$28.3M
3
ASND icon
Ascendis Pharma A/S
ASND
+$27.8M
4
CTLT
CATALENT, INC.
CTLT
+$23M
5
MASI
Masimo
MASI
+$18.2M

Top Sells

Rank Stock Value
1
QGEN icon
Qiagen
QGEN
+$26.7M
2
AMRN
Amarin Corp
AMRN
+$24.9M
3
OGN icon
Organon & Co
OGN
+$21.2M
4
DHR icon
Danaher
DHR
+$17.4M
5
AMN icon
AMN Healthcare
AMN
+$15.8M

Sector Composition

Rank Sector Weight
1 Healthcare 80.74%
2 Miscellaneous 17.65%
3 Industrials 1.16%
4 Financials 0.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TLGT
101
DELISTED
Teligent, Inc
TLGT
$427K 0.03%
1,069,465
-1,430,795
-57% -$626K
CCRN
102
DELISTED
Cross Country Healthcare
CCRN
$425K 0.03%
20,000
-10,810
-35% -$203K
FSTX
103
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$366K 0.03%
49,933
-50,067
-50% -$344K
KRRO icon
104
Korro Bio
KRRO
$190M
$212K 0.01%
+600
New +$236K
FBRX icon
105
PUT
Forte Biosciences
FBRX
$210K 0.01%
+2,828
New +$1.57M
AFMD
106
DELISTED
Affimed
AFMD
– –
-56,694
Closed -$4.82M
ARKG icon
107
CALL
ARK Genomic Revolution ETF
ARKG
$1.88B
– –
-199,000
Closed -$18.4M
BIIB icon
108
CALL
Biogen
BIIB
$32.3B
– –
-115,600
Closed -$40M
BIIB icon
109
PUT
Biogen
BIIB
$32.3B
– –
-2,000
Closed -$693K
CGEM icon
110
Cullinan Oncology
CGEM
$1.4B
– –
-163,880
Closed -$4.22M
CI icon
111
Cigna
CI
$73.7B
– –
-41,745
Closed -$9.9M
HUMA icon
112
Humacyte
HUMA
$181M
– –
-205,026
Closed -$2.09M
IMVT icon
113
Immunovant
IMVT
$8.51B
– –
-110,183
Closed -$1.16M
IPSC icon
114
Century Therapeutics
IPSC
$367M
– –
-100,901
Closed -$2.96M
MCRB icon
115
Seres Therapeutics
MCRB
$51.3M
– –
-2,978
Closed -$1.42M
OCUL icon
116
Ocular Therapeutix
OCUL
$2.28B
– –
-150,000
Closed -$2.13M
OGN icon
117
Organon & Co
OGN
$3.61B
– –
-699,696
Closed -$21.2M
OMCL icon
118
Omnicell
OMCL
$1.51B
– –
-98,366
Closed -$14.9M
OPCH icon
119
Option Care Health
OPCH
$3.58B
– –
-289,297
Closed -$6.33M
QQQ icon
120
PUT
Invesco QQQ Trust
QQQ
$489B
– –
-250,000
Closed -$88.6M
TDOC icon
121
CALL
Teladoc Health
TDOC
$1.18B
– –
-40,000
Closed -$6.65M
TGTX icon
122
TG Therapeutics
TGTX
$8.26B
– –
-69,760
Closed -$2.71M
TIP icon
123
PUT
iShares TIPS Bond ETF
TIP
$15B
– –
-70,000
Closed -$8.96M
VRTX icon
124
Vertex Pharmaceuticals
VRTX
$137B
– –
-54,500
Closed -$10.6M
XBI icon
125
CALL
State Street SPDR S&P Biotech ETF
XBI
$11.3B
– –
-200,000
Closed -$27.1M
2 3 4
5
6

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q3 2021 Portfolio in Review

As of Q3 2021, Eversept Partners held 129 positions worth $1.45B, down 3.6% from $1.5B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Eversept Partners deployed $154M of net new capital in Q3 2021, opening 42 new positions and adding to 32 existing holdings. Its largest new stake was Labcorp: 149,354 shares worth $36.1M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, up from 65% a quarter earlier, followed by Miscellaneous and Industrials.

On the sell side, the largest reduction was Qiagen, an estimated $26.7M trimmed.

  • Eversept Partners's largest Q3 2021 buy was Labcorp: 149,354 shares worth $36.1M.
  • Eversept Partners added most to Community Health Systems in Q3 2021, an estimated $28.3M increase.
  • Eversept Partners's biggest Q3 2021 reduction was Qiagen, cutting an estimated $26.7M.
  • Eversept Partners fully exited Organon & Co in Q3 2021, selling an estimated $21.2M.
  • Eversept Partners's ten largest holdings make up 43% of its $1.45B portfolio in Q3 2021.
  • Eversept Partners opened 42 new positions and closed 24 in Q3 2021.
  • Eversept Partners's portfolio value fell 3.6% quarter-over-quarter to $1.45B.

Based on Eversept Partners's 13F filing for Q3 2021, filed 15 Nov 2021.